Pediatric post-marketing safety systems in North America: assessment of the current status.

Autor: McMahon AW; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA., Wharton GT; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA., Bonnel R; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA., DeCelle M; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA., Swank K; Office of Pharmacovigilance and Epidemiology, US Food and Drug Administration, Silver Spring, MD, USA., Testoni D; Duke Clinical Research Institute, Duke School of Medicine, Durham, NC, USA., Cope JU; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA., Smith PB; Duke Clinical Research Institute, Duke School of Medicine, Durham, NC, USA., Wu E; Office of Pharmacovigilance and Epidemiology, US Food and Drug Administration, Silver Spring, MD, USA., Murphy MD; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA.
Jazyk: angličtina
Zdroj: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2015 Aug; Vol. 24 (8), pp. 785-92. Date of Electronic Publication: 2015 Jun 22.
DOI: 10.1002/pds.3813
Abstrakt: Purpose: It is critical to have pediatric post-marketing safety systems that contain enough clinical and epidemiological detail to draw regulatory, public health, and clinical conclusions. The pediatric safety surveillance workshop (PSSW), coordinated by the Food and Drug Administration (FDA), identified these pediatric systems as of 2010. This manuscript aims to update the information from the PSSW and look critically at the systems currently in use.
Methods: We reviewed North American pediatric post-marketing safety systems such as databases, networks, and research consortiums found in peer-reviewed journals and other online sources. We detail clinical examples from three systems that FDA used to assess pediatric medical product safety.
Results: Of the 59 systems reviewed for pediatric content, only nine were pediatric-focused and met the inclusion criteria. Brief descriptions are provided for these nine. The strengths and weaknesses of three systems (two of the nine pediatric-focused and one including both children and adults) are illustrated with clinical examples.
Conclusions: Systems reviewed in this manuscript have strengths such as clinical detail, a large enough sample size to capture rare adverse events, and/or a patient denominator internal to the database. Few systems include all of these attributes. Pediatric drug safety would be better informed by utilizing multiple systems to take advantage of their individual characteristics.
(Copyright © 2015 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: